The American Journal of Managed Care

Subcutaneous Amivantamab Allows for Potential Increases in Adherence, Treatment Options: Martin Dietrich, MD, PhD

The approval of subcutaneous amivantamab allows physicians flexibility in offering treatment for non–small cell lung cancer.
The American Journal of Managed Care

FDA Approves Subcutaneous Mosunetuzumab for R/R Follicular Lymphoma

The FDA has granted approval to a subcutaneous formulation of mosunetuzumab (Lunsumio VELO; Genentech/Roche) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma ...

FDA approves first subcutaneous drug for EGFR-mutated non-small cell lung cancer

The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and ...

Genentech's subcutaneous Lunsumio gains FDA approval

The US FDA has approved a subcutaneous version of Roche (RHHBY)-owned Genentech's follicular lymphoma treatment, Lunsumio (mosunetuzumab). Lunsumio VELO takes about one minute to administer, compared ...
Zacks Investment Research on MSN

J&J wins FDA nod for subcutaneous version of NSCLC drug Rybrevant (revised)

Johnson & Johnson JNJ announced that the FDA has approved the subcutaneous (under the skin or SC) formulation of its EGFR/MET ...